Rhythm Pharmaceuticals Inc (RYTM) - News Archive

In a significant stride towards understanding and addressing the debilitating impacts of fatigue in patients with craniopharyngioma, Rhythm Pharmaceuticals, a biopharmaceutical company focused on innovative therapies fo...

Rhythm Pharmaceuticals: Navigating Growth Amidst Challenges and BreakthroughsRhythm Pharmaceuticals, Inc. has made significant strides and faced notable challenges in 2024, as articulated in their preliminary financial...

Rhythm Pharmaceuticals’ New Milestone: A Beacon of Hope or a Signal of Trouble?BOSTON, Dec. 20, 2024 – In a significant move that underscores the urgency in treating rare genetic disorders, Rhythm Pharmaceuticals, Inc....

Rhythm Pharmaceuticals, Inc. a biopharmaceutical company headquartered in Boston and traded on Nasdaq under the ticker RYTM, has announced an expanded marketing authorization for its drug, IMCIVREE (setmelanotide), in t...

In an exciting announcement, Rhythm Pharmaceuticals has unveiled five impactful presentations at the upcoming European Society for Paediatric Endocrinology (ESPE) 2024, focusing on real-world data and therapeutic advanc...

Rhythm Pharmaceuticals, Inc. a biopharmaceutical company focused on rare neuroendocrine diseases, has recently published pivotal data from its Phase 3 VENTURE trial in the peer-reviewed journal The Lancet Diabetes & End...

At ObesityWeek 2024, Rhythm Pharmaceuticals took center stage by presenting compelling new data on the efficacy of setmelanotide, a breakthrough therapy aimed at battling acquired hypothalamic obesity, a complex and cha...

In a strategic move that underscores its ongoing commitment to enhancing operational capabilities, Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) has announced the granting of employment inducement grants to four new emplo...

Rhythm Pharmaceuticals, a renowned biopharmaceutical company dedicated to improving the lives of patients and families affected by rare neuroendocrine diseases, recently made an exciting announcement. On August 8, 2024,...

Boston-based biopharmaceutical company, Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), known for its focus on rare neuroendocrine diseases, recently announced the granting of inducement restricted stock units (RSUs) to si...

Rhythm Pharmaceuticals, a biopharmaceutical company specializing in rare neuroendocrine diseases, recently announced inducement equity grants to new employees. This news comes in the context of previous announcements re...

:This article discusses the ground-breaking research presented by Rhythm Pharmaceuticals at ENDO 2024, which provides vital insights into the patient experiences associated with hyperphagia in hypothalamic obesity. Hypo...

In recent news, Rhythm Pharmaceuticals announced that their breakthrough drug IMCIVREE (setmelanotide) has received a positive recommendation from the National Institute for Health and Care Excellence (NICE). This recom...

Rhythm Pharmaceuticals Awards Employment Inducement Grants, Reflecting Optimism in Future GrowthIn an exciting development, Rhythm Pharmaceuticals, Inc. has recently announced the granting of inducement restricted stock...

At the Pediatric Endocrine Society Annual Meeting, Rhythm Pharmaceuticals unveiled data from their Phase 3 pediatrics trial, demonstrating the potential of setmelanotide in treating obesity in young patients. These find...

In a recent groundbreaking study published in The Lancet Diabetes & Endocrinology, Rhythm Pharmaceuticals announced successful results from a Phase 2 clinical trial involving the use of setmelanotide therapy for the tre...

Rhythm Pharmaceuticals, a biopharmaceutical company dedicated to rare neuroendocrine diseases, has recently announced inducement equity grants to new employees. This follows previous grants made in March and October of...

In recent pharmaceutical news, Rhythm Pharmaceuticals has made significant strides in the development of MC4R-specific agonists, aimed at tackling obesity-related disorders. This article will discuss the recent developm...

Rhythm Pharmaceuticals, a renowned biopharmaceutical company dedicated to transforming the lives of patients battling rare neuroendocrine diseases, has recently made a significant announcement. On March 6, 2024, the Com...

Rhythm Pharmaceuticals Expands Clinical Development Plan for Setmelanotide in JapanRhythm Pharmaceuticals has recently announced the expansion of its clinical development plan for Setmelanotide in Japan, specifically ta...